Frailty linked to diminished quality of life in cancer and transplant survivors

As noted in the abstract, physical frailty is not well characterized in breast cancer (BC) and hematopoietic cell transplant (HCT) survivors as a sign of accelerated aging. Its correlation with outcomes and quality of life (QOL) is not defined.

"…this pilot study demonstrates the alarmingly high prevalence of frailty in two growing cohorts of survivors, those with BC and those undergoing HCT, with detrimental effects of physical functioning, quality of life and overall wellbeing."

Their data demonstrate the association between frailty and the senescence marker p16INK4a, years after the completion of treatment. These findings further support the need for well-designed senolytic trials in cancer survivors.

Source:

Aging-US

Journal reference: